MoonLake Immunotherapeutics (MLTX) Competitors

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations, community ranking and institutional ownership.

Do institutionals & insiders hold more shares of MLTX or ASND?

93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Do analysts rate MLTX or ASND?

MoonLake Immunotherapeutics currently has a consensus price target of $80.50, suggesting a potential upside of 130.66%. Ascendis Pharma A/S has a consensus price target of $204.64, suggesting a potential upside of 35.53%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe MoonLake Immunotherapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Which has preferable valuation & earnings, MLTX or ASND?

MoonLake Immunotherapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$36.01M	-$1.89	-18.47
Ascendis Pharma A/S	$363.64M	25.20	-$409.12M	-$7.10	-21.27

Does the MarketBeat Community prefer MLTX or ASND?

Ascendis Pharma A/S received 379 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 81.93% of users gave MoonLake Immunotherapeutics an outperform vote while only 66.82% of users gave Ascendis Pharma A/S an outperform vote.

Company	Underperform	Outperform
MoonLake Immunotherapeutics	Outperform Votes 68 81.93%	Underperform Votes 15 18.07%
Ascendis Pharma A/S	Outperform Votes 447 66.82%	Underperform Votes 222 33.18%

Does the media prefer MLTX or ASND?

In the previous week, MoonLake Immunotherapeutics and MoonLake Immunotherapeutics both had 9 articles in the media. Ascendis Pharma A/S's average media sentiment score of 1.61 beat MoonLake Immunotherapeutics' score of 1.08 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Is MLTX or ASND more profitable?

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -104.54%. Ascendis Pharma A/S's return on equity of 0.00% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-15.54%	-15.09%
Ascendis Pharma A/S	-104.54%	N/A	-39.23%

Which has more volatility & risk, MLTX or ASND?

MoonLake Immunotherapeutics has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.

Summary

MoonLake Immunotherapeutics beats Ascendis Pharma A/S on 10 of the 17 factors compared between the two stocks.